UroGen Pharma Ltd.
URGN
$24.38
-$4.08-14.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.49% | 19.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.49% | 19.56% | |||
| Cost of Revenue | -7.66% | 52.36% | |||
| Gross Profit | 17.13% | 15.29% | |||
| SG&A Expenses | -13.00% | 23.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.44% | 14.86% | |||
| Operating Income | 33.93% | -12.28% | |||
| Income Before Tax | 29.69% | -12.60% | |||
| Income Tax Expenses | -203.84% | 158.93% | |||
| Earnings from Continuing Operations | 33.23% | -13.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.23% | -13.91% | |||
| EBIT | 33.93% | -12.28% | |||
| EBITDA | 36.17% | -12.28% | |||
| EPS Basic | 33.67% | -13.15% | |||
| Normalized Basic EPS | 30.15% | -11.84% | |||
| EPS Diluted | 33.67% | -13.15% | |||
| Normalized Diluted EPS | 30.15% | -11.84% | |||
| Average Basic Shares Outstanding | 0.67% | 0.67% | |||
| Average Diluted Shares Outstanding | 0.67% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||